Division of Endocrinology, Metabolism and Nutrition, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Best Pract Res Clin Endocrinol Metab. 2012 Jun;26(3):281-9. doi: 10.1016/j.beem.2011.10.003.
Graves' ophthalmopathy is an inflammatory autoimmune disorder of the orbit. The close clinical and temporal relationships between Graves' hyperthyroidism and ophthalmopathy have long suggested that both conditions derive from a single systemic process and share the thyrotropin receptor as a common autoantigen. This receptor is expressed not only in thyroid follicular cells, but also in orbital fibroblasts with higher levels measured in orbital cells from ophthalmopathy patients than in cells from normal individuals. Recent studies from several laboratories have shown that thyrotropin receptor activation in orbital fibroblasts enhances hyaluronic acid synthesis and adipogenesis, both cellular functions that appear to be upregulated in the diseased orbit. The phosphoinositide 3-kinase/Akt signaling cascade, along with other effector pathways including adenylyl cyclase/cAMP, appears to mediate these processes. Future therapies for this condition may involve inhibition of thyrotropin receptor signaling in orbital fibroblasts.
格雷夫斯眼病是一种眼眶炎症性自身免疫性疾病。格雷夫斯甲亢与眼病之间密切的临床和时间关系长期以来表明,这两种情况都源于单一的全身过程,并共享促甲状腺激素受体作为共同的自身抗原。这种受体不仅在甲状腺滤泡细胞中表达,而且在眼眶成纤维细胞中也有表达,在眼病患者的眼眶细胞中测量到的水平高于正常个体的细胞。来自几个实验室的最近研究表明,眼眶成纤维细胞中促甲状腺激素受体的激活增强了透明质酸的合成和脂肪生成,这两种细胞功能似乎在患病眼眶中上调。磷酸肌醇 3-激酶/Akt 信号级联反应,以及包括腺苷酸环化酶/cAMP 在内的其他效应途径,似乎介导了这些过程。这种疾病的未来治疗方法可能涉及抑制眼眶成纤维细胞中促甲状腺激素受体的信号。